Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading
January 15, 2015
- Wholesalers Must Revamp Biz Model to Cope with Change in Sales Mix: JPWA Chief
January 14, 2015
- Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President
January 9, 2015
- Pharma Biz Leader Airs Concern over Effective Tax Hikes
January 8, 2015
- Sumitomo Dainippon President Praises Govt’s Healthcare Measures
January 6, 2015
- FPMAJ Chairman Wishes for Good Environment for Drug Innovation in 2015
January 1, 2015
- FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman
December 24, 2014
- EFPIA Japan Chairman Calls for More Rewards for Innovation
December 22, 2014
- Bristol-Myers Reprimanded by JPMA over Misconduct in Sprycel Trial
December 19, 2014
- JPMA to Formulate Strict Official Policy on Advertising Aimed at Medical Institutions by End of Fiscal Year
December 19, 2014
- JMA Chief Lauds Big Win by LDP, Komeito in Lower House Race
December 17, 2014
- JPMA to Require Disclosure of Clinical R&D Costs in More Detail
December 15, 2014
- JMA, JAMS Call for Enhancing Support for Girls Suffering from Post-HPV Vaccine Reactions
December 12, 2014
- JPMA President Opposes Annual NHI Price Revision
November 21, 2014
- PhRMA Chair Prods Japan to Permanently Install Key Pricing Premium
November 20, 2014
- Ihoken Proposes Revision of Compensation Guidelines to Include Compensation for Injury Due to Anticancer Drugs
November 20, 2014
- Mr Aoyagi of JPMA Calls for Negotiating Invoice Prices for Individual Products
November 17, 2014
- No Nippon Pharmacy Association Affiliated Pharmacy Will Be Subject to Medical Fee Cut Rule: Survey
November 17, 2014
- JPMA, JPPA, and JPWA Express Strong Opposition to Annual NHI Price Revision
November 4, 2014
- EFPIA Japan Official Calls for More-Effective Use of Surplus Raw Plasma
October 30, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…